Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dewu Zhong is active.

Publication


Featured researches published by Dewu Zhong.


International Journal of Biological Macromolecules | 2013

Optimization extraction of Ganoderma lucidum polysaccharides and its immunity and antioxidant activities.

Ke Pan; Qunguang Jiang; Guoqing Liu; Xiongying Miao; Dewu Zhong

Extraction of Ganoderma lucidum polysaccharides (GLP) was optimized by response surface method (RSM). By running the optimization program with design expert within the experimental range investigated, the following optimum values were obtained: extraction time 230 min; extraction temperature 95 °C, and extraction number 5. The predicted polysaccharides production was 1.45%. Results showed that GLP significantly reduced the levels of serum IL-6 and TNF-α levels and increased the levels of serum IL-2, IL-4 and IL-10 in GLP-treated rats compared to gastric cancer model rats. In addition, administration of Ganoderma lucidum polysaccharides to GLP-treated group of rats improved the levels of serum and gastric tissue SOD, CAT and GSH-Px toward the control values in a dose-dependent manner. These findings show that GLP can enhance immunity and antioxidant activities in gastric cancer rats.


Cancer Genetics and Cytogenetics | 2008

High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma

Xiongying Miao; Guoxing Liu; Xundi Xu; Chengzhi Xie; Fadi Sun; Yaohui Yang; Tao Zhang; Songwen Hua; Wentao Fan; Qinglong Li; Shengfu Huang; Guoli Liu; Dewu Zhong

The vanilloid receptor-1 (VR1) is a ligand-gated, nonselective cation channel expressed predominantly by sensory neurons, but is also involved in carcinogenesis. To elucidate its role in hepatocarcinogenesis, we analyzed the expression of VR1 receptor in tumor and nontumor tissues from human hepatocellular carcinoma (HCC) samples. In situ hybridization analysis showed overexpression of VR1 mRNAs in 9/15 (60.0%) noncancer and 6/15 (40.0%) HCC samples. Immunohistochemistry of 62 HCC samples showed the expression of VR1 increased from normal liver or chronic hepatitis to cirrhosis. Marked expression of VR1 was noted in the majority [31/38 (81.6%)] of cirrhotic liver samples. In HCC, high expression of VR1 was observed in 30/62 (48.4%) cases. Clinicopathologic evaluation indicated a significant correlation between VR1 expression and histopathologic differentiation (P=0.001). Univariate analysis indicated that disease-free survival was significantly better in HCC patients with high versus those with low VR1 expression levels (P= 0.021). Our results indicate that VR1 has anti-HCC progression effects and can be potentially used as a prognostic indicator of HCC. The results suggest the potential beneficiary effects of VR1 expression on the prognosis of patients with HCC.


Surgery | 2009

Anatomic resection of segment VIII of liver for hepatocellular carcinoma in cirrhotic patients based on an intrahepatic Glissonian approach

Hu Jx; Dai Wd; Xiongying Miao; Dewu Zhong; Shengfu Huang; Yu Wen; Xiong Sz

BACKGROUND Isolated segmentectomy VIII is a technically demanding operative procedure and is reported only rarely. To our knowledge, no reports on anatomic segmentectomy based on an intrahepatic approach have been described. For cirrhotic patients with hepatocellular carcinoma (HCC) limited to segment VIII, this is a parenchyma-preserving hepatectomy that can be tolerated. METHODS Eighteen patients with HCC underwent anatomic segment VIII segmentectomy from January 2005 to January 2008 in our institution. The operative techniques, postoperative, and oncologic outcomes were reviewed. RESULTS Anatomic segmentectomy VIII was feasible with the technology described herein in all patients. The perioperative and oncologic outcomes were comparable with those of other similar hepatic resections. The median follow-up time was 28 months. The 3-year survival rate was 65%. CONCLUSION Although complex and technically demanding, an intrahepatic Glissonian approach for anatomic segmentectomy of segment VIII is an oncologically radical but parenchyma-sparing hepatic resection. In terms of preserving greater functioning liver parenchyma, it may be a safe and effective alternative to extensive hepatectomy.


Cancer Genetics and Cytogenetics | 2010

Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma

Guoxing Liu; Chengzhi Xie; Fadi Sun; Xundi Xu; Yaohui Yang; Tao Zhang; Yuansheng Deng; Dianchen Wang; Zhao Huang; Leping Yang; Shengfu Huang; Guoli Liu; Dewu Zhong; Xiongying Miao

Transient receptor potential vanilloid 2 (TRPV2), one of the members of TRP (transient receptor potential) superfamily of ion channels, has been suggested to contribute to pain associated with inflammation or neuropathy. To investigate its role in hepatocarcinogenesis, we examined the expression of TRPV2 in human hepatocellular carcinoma (HCC) samples and analyzed the association of TRPV2 expression with its clinical significance. TRPV2 expression in 55 HCC patients was examined by immunohistochemistry, and the correlation between TRPV2 levels and clinicopathologic parameters was analyzed. Thirteen paired HCC specimens and their nontumor counterparts were investigated by quantitative real-time polymerase chain reaction (RT-PCR) and Western blotting, respectively. Quantitative RT-PCR and Western blotting analysis revealed that expression of TRPV2 at both the mRNA and protein levels were increased in cirrhotic livers compared with chronic hepatitis, whereas that also occurred in moderately and well-differentiated tumors compared with that of poorly differentiated tumors. Immunohistochemistry of the 55 HCC samples showed that the expression of TRPV2 increased when going from normal liver or chronic hepatitis to cirrhosis. Increased TRPV2 expression was observed in tissues of liver cirrhosis (31/37, 83.8%). In HCC, increased expression of TRPV2 was identified in 16/55 (29%) cases. Clinicopathologic assessment suggested a significant association between TRPV2 expression and portal vein invasion and histopathologic differentiation (P = 0.036 and 0.001, respectively). Our data suggest that TRPV2 plays a role in human hepatocarcinogenesis and might be a prognostic marker of patients with HCC.


Experimental and Therapeutic Medicine | 2017

MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells

Qiongyan Zou; Yi W; Jianghai Huang; Fenfen Fu; Gannong Chen; Dewu Zhong

MicroRNAs (miRs) are a type of small non-coding RNA that serve crucial roles in the development and progression of breast cancer. However, the exact role and underlying molecular mechanism of miR-375 in mediating the growth and metastasis of breast cancer remains unknown. In the present study, reverse transcription-quantitative polymerase chain reaction and western blot analysis were conducted to examine RNA and protein expression. A luciferase reporter assay was performed to determine the association between miR-375 and paired box 6 (PAX6). The results of the current study indicate that the expression of miR-375 was reduced in breast cancer tissues compared with matched adjacent normal tissues. Transfection with miR-375 mimics led to a significant increase in levels of miR-375 in human breast cancer Michigan Cancer Foundation (MCF)-7 cells (P<0.05). The increase in miR-375 expression caused a significant decrease in the viability, migration and invasion of MCF-7 cells (P<0.05), accompanied by a reduced expression of matrix metalloproteinase (MMP) 2 and MMP9 proteins. Luciferase reporter assay identified PAX6 as a novel target of miR-375 and miR-375 in turn, negatively regulated the protein expression of PAX6 in MCF-7 cells. By contrast, overexpression of PAX6 led to a significant increase in MCF-7 cell viability (P<0.01) but did not affect the migration and invasion of MCF-7 cells, suggesting that the inhibitory effect of miR-375 on MCF-7 cell viability may be occurring, in part, via the direct targeting of PAX6.


European Journal of Medical Research | 2013

Ferroportin in the progression and prognosis of hepatocellular carcinoma.

Qin Wang; Jun Zhou; Dewu Zhong; Jiangsheng Huang

BackgroundHepatocellular carcinoma (HCC) is the fifth most common malignant tumor in men and the seventh in women and understanding the molecular mechanisms of HCC and establishing more effective therapies are critical and urgent issues. Our objective was to study the expression of ferroportin in hepatocellular carcinoma (HCC) tissue samples and the relationship between ferroportin expression and HCC characteristics.MethodsSixty HCC tissues and their corresponding para-cancer liver tissues (PCLT) were obtained from sixty HCC patients who had undergone hepatectomy in the Second Xiangya Hospital of Central South University. Ten normal liver tissue samples were also obtained as a control. Immunohistochemistry (IHC) was performed to analyze the ferroportin expression in HCC, and the relationship between ferroportin expression and HCC clinical pathological characteristics also was analyzed. For the evaluation of IHC results, the comprehensive scoring criteria were met according to the staining intensity and the number of positive staining cells. Western blotting was performed to detect the expression level of ferroportin in HCC cell lines.ResultsFerroportin expression in HCC tissue was significantly lower compared to PCLT and normal liver tissue (P <0.05). Moreover, ferroportin expression was related to liver cancer cell de-differentiation, the severity degree in TNM staging, Edmondson-Steiner grading, intrahepatic metastasis and portal vein invasion. In addition, high expression of ferroportin was observed in normal human liver cell lines L02 and HL7702, whereas weak positive expression and even negative expression of ferroportin were observed in HCC cell lines FOCUS, MHCC-97H, HepG2 and SMMC-7721. Furthermore, among the four kinds of HCC cell lines, the expression level of ferroportin was the lowest in MHCC-97H cells.ConclusionsFerroportin expression level declines along with the progression of liver cancer, suggesting that the reduction of ferroportin may serve as an important marker for poor HCC prognosis and as a new therapeutic target.


International Journal of Molecular Medicine | 2015

Numb downregulation suppresses cell growth and is associated with a poor prognosis of human hepatocellular carcinoma

Chengzhi Xie; Zhenhui Lu; Guoxing Liu; Yu Fang; Jiefeng Liu; Zhao Huang; Fusheng Wang; Xiaolong Wu; Xiaohua Lei; Xiaocheng Li; Yueming Zhang; Zecheng Hu; Ke Qian; Hu Jx; Shengfu Huang; Dewu Zhong; Xundi Xu

Numb, an endocytic adaptor, is a known cell fate determinant that participates in asymmetric cell division. The present study aimed to explore the potential roles of Numb in hepatocarcinogenesis. Numb expression was investigated in hepatocellular carcinomas (HCC) with reverse transcription-quantitative polymerase chain reaction and immunohistochemical examination; its association with the prognosis of HCC patients was analyzed. In addition, the effects of Numb deletion on proliferation of HCC cells and its relevant molecules were evaluated in Huh7 and HepG2 cells. Numb overexpression was observed in 62% of adjacent non-tumor tissues and 46% of tumor tissues. Overexpression of Numb in HCC was associated with histological grade, portal vein invasion and the number of tumors (P=0.001, 0.022 and 0.034 respectively). Multivariate analysis revealed that Numb expression was an independent prognostic indicator of HCC patients. Methylation of the Numb promoter contributed to hepatocarcinogenesis. In vitro assays demonstrated that Numb silencing resulted in inhibition of cell proliferation, induction of apoptosis, down-regulation of cyclin-dependent protein kinase 4 (CDK4) and S-phase kinase-associated protein 2 (SKP2), and upregulation of Bcl-2 homologous antagonist/killer (BAK) and cyclin-dependent kinase inhibitor 1 (p21). The present study suggests that downregulation of Numb inhibits colony formation and cell proliferation, induces apoptosis of HCC cells and independently predicts the poor prognosis of HCC patients. Thus, Numb has a potential role in the development and progression of HCC.


Hepato-gastroenterology | 2011

Null-margin bisegmentectomy VII-VIII for hepatocellular carcinoma in cirrhotic patients.

Jiang-Sheng Huang; Dai Wd; Xiongying Miao; Dewu Zhong; Xiong Sz; Hu Jx

BACKGROUND/AIMS Preservation of functional liver parenchyma should be a priority in hepatic surgery to avoid postoperative liver failure and enhance the opportunity to perform repeat resection in case of tumor recurrence. METHODOLOGY A tumor localized in segments VII, VIII and adhering to or compressing the middle hepatic vein sometimes indicates a need to perform bisegmentectomy VII-VIII without surgical margin. From June 2006 to June 2011, fourteen patients with such a tumor underwent null-margin bisegmentectomy VII-VIII in our hospital. We retrospectively review our experience with this uncommon and technique-challenging hepatic resection. RESULTS Mean intraoperative blood loss was estimated to be 300 mL and only four patients required blood transfusions less than 4U each person. Mean postoperative hospitalization was 11.2 days. Postoperative complications were encountered in 28.5% of patients and there was no postoperative mortality. Median overall and disease-free survivals were 35 and 23 months, respectively. CONCLUSIONS The lack of ability to obtain an adequate surgical margin should not be considered as a contraindication for hepatectomy of HCC. In patients with impaired liver functional reserve and with right superiorly located tumors, the preservation of the middle hepatic vein should take priority and null-margin bisegmentectomy VII-VIII for HCC should be recommended.


Oncology Letters | 2013

Peliosis hepatis mimicking cancer: A case report

Weidong Dai; Dewu Zhong

Peliosis hepatis (PH) is a rare condition characterized by the presence of blood-filled cavities within the liver. The etiology of PH remains unknown, but it has been reported to be associated with infections or malignancies. However, the cause of PH is not clear in 20–50% of patients. The current study presents the case of a 19-year-old male who presented with right upper quadrant pain that had lasted for three days. The patient was a student with no previous medical history. Contrast-enhanced computer tomography (CT) and ultrasonography showed a neoplasm in the right liver and a diagnosis of primary liver cancer was made due to the manifestation of the disease and the results of physical tests. The individual was treated successfully with an irregular right hemihepatectomy and was in good health at 6-months post-surgery. A tissue specimen was obtained and determined to be PH by pathological examination and immunohistochemistry analysis. Consequently, a diagnosis of PH must be considered in cases like this.


European Journal of Medical Research | 2015

RETRACTED ARTICLE: Ferroportin in the progression and prognosis of hepatocellular carcinoma

Qin Wang; Jun Zhou; Dewu Zhong; Jiangsheng Huang

Retraction The Publisher and Editor regretfully retract this article [1] because the peer-review process was inappropriately influenced and compromised. As a result, the scientific integrity of the article cannot be guaranteed. A systematic and detailed investigation suggests that a third party was involved in supplying fabricated details of potential peer reviewers for a large number of manuscripts submitted to different journals. In accordance with recommendations from COPE we have retracted all affected published articles, including this one. It was not possible to determine beyond doubt that the authors of this particular article were aware of any third party attempts to manipulate peer review of their manuscript.

Collaboration


Dive into the Dewu Zhong's collaboration.

Top Co-Authors

Avatar

Xiongying Miao

Central South University

View shared research outputs
Top Co-Authors

Avatar

Hu Jx

Central South University

View shared research outputs
Top Co-Authors

Avatar

Dai Wd

Central South University

View shared research outputs
Top Co-Authors

Avatar

Shengfu Huang

Central South University

View shared research outputs
Top Co-Authors

Avatar

Xundi Xu

Central South University

View shared research outputs
Top Co-Authors

Avatar

Chengzhi Xie

Central South University

View shared research outputs
Top Co-Authors

Avatar

Guoxing Liu

Central South University

View shared research outputs
Top Co-Authors

Avatar

Xiong Sz

Central South University

View shared research outputs
Top Co-Authors

Avatar

Jun Zhou

Central South University

View shared research outputs
Top Co-Authors

Avatar

Yi Liu

Central South University

View shared research outputs
Researchain Logo
Decentralizing Knowledge